Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06515314 | HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors | recruiting | Phase 1 | 12 | Shanghai Ruiliyuan Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259590 | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | recruiting | Phase 1 / Phase 2 | 126 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 2, 2025 |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07178171 | A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC | recruiting | Phase 1 | 30 | Xijing HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05558904 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06675136 | Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases | recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06198296 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | recruiting | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04361708 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies(I-FLOAT) | recruiting | Phase 1 | 54 | University of ChicagoOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06182072 | ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | Phase 1 | 46 | ProDa BioTech, LLCINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05808634 | Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. | recruiting | Phase 1 | 168 | BioAtla, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06902389 | A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06374485 | Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment | recruiting | Phase 1 | 18 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | recruiting | Phase 1 | 21 | GONGCHU Biotechnology Co., LtdOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07123545 | Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06976892 | Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer(IDOL) | recruiting | Phase 1 | 33 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06695026 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 45 | Rznomics, Inc.OTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07077356 | Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06329973 | Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer | recruiting | Phase 1 / Phase 2 | 70 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05797805 | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Iterion TherapeuticsINDUSTRY | 2 | Jul 4, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07018518 | PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma | recruiting | Phase 1 | 25 | Chinese PLA General HospitalOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors(RIOT3) | recruiting | Phase 1 | 18 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05518253 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Weijia Fang, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06995105 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06741020 | Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma(HAICI) | recruiting | Phase 1 / Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04947189 | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer(4CAST) | recruiting | Phase 1 / Phase 2 | 65 | St Vincent's Hospital, SydneyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06911255 | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 24 | Yoon Jun KimOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06961617 | Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | Phase 1 / Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05687747 | Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma | recruiting | Phase 1 | 100 | National University Hospital, SingaporeOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy(CIRCADIAN) | recruiting | Phase 1 / Phase 2 | 20 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.OTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06773312 | BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 1 | 80 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | recruiting | Phase 1 | 80 | Sichuan UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2025source: clinicaltrials